Global Multiple System Atrophy Market Pipeline Review, H1 2018

0


Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H1 2018 provides an overview of the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline landscapes.

Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs the body’s involuntary functions (blood pressure, heart rate, bladder function, and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence, and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson’s medications.

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and latest news and press releases.

The Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipelines guides also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 4, 6 and 1 respectively.

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline guides help in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and help to create effective counter-strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real-time basis.

To know more, click on the link below:

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H1 2018

Related reports:

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H2 2017

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H2 2016

Contact us:

Ken research

Ankur Gupta, head marketing & communications

sales@kenresearch.com

+91-9015378249

Share.

Comments are closed.